trending Market Intelligence /marketintelligence/en/news-insights/trending/4maga8qx0b3tbxtitanqia2 content esgSubNav
In This List

Sun BioPharma board member resigns

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Sun BioPharma board member resigns

Sun BioPharma Inc. said that Dalvir Gill has resigned from the company's board, effective Aug. 30.

The company said in a Sept. 6 filing that Gill resigned in order to focus on other responsibilities.

Gill joined the board of the Waconia, Minn.-based biotechnology company as an independent director in March 2016. He has served as the CEO of TransCelerate BioPharma Inc. since January 2013.

Sun BioPharma develops disruptive therapeutics for severe unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer.